GlassScriptPhysician profile
James R Spires
NPI 1992799571
$1,472.61
in general payments reported to CMS, 2019-2025
15 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.43 · 2020: $102 · 2021: $310 · 2022: $187 · 2023: $223 · 2024: $200 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678 · Education: $99.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.52 |
| Education | $99.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $465.10 | 2019-2025 | |
| Optinose US, INC. | $339.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $277.57 | 2019-2025 | Dupixent |
| Stryker Corporation | $71.71 | 2019-2023 | Xpress Ent Dilation System |
| Ars Pharmaceuticals Operations, INC. | $52.03 | 2025 | Neffy |
| Phathom Pharmaceuticals, INC. | $46.33 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $45.48 | 2021-2025 | Nucala |
| Merck Sharp & Dohme LLC | $37.46 | 2021-2023 | |
| Abbvie INC. | $25.45 | 2023 | Qulipta |
| Medtronic, INC. | $24.87 | 2023 | Novapak |
| Astrazeneca Pharmaceuticals LP | $23.78 | 2025 | Tezspire |
| Eyevance Pharmaceuticals LLC | $21.47 | 2021 | |
| Hikma Pharmaceuticals USA | $15.11 | 2023 | Ryaltris |
| Amneal Pharmaceuticals LLC | $14.41 | 2025 | Unithroid |
| Aerin Medical INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Spires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.